Depo-Provera Settlement in MDL 3140: Who Qualifies and the Deadline
Updated

Short answer
The Depo-Provera settlement resolves most of the federal meningioma lawsuits against Pfizer in MDL No. 3140, and as of November 2026 the court’s orders give November 30, 2026 as the deadline for eligible claimants to register.1 Its terms are confidential, and the parties expected about 80 percent of plaintiffs to qualify.2
On this page (11)
How MDL 3140 began
The federal Depo-Provera cases were gathered in one court by the Judicial Panel on Multidistrict Litigation on February 7, 2025. At that point there were 27 lawsuits in eight federal districts and 41 related actions in fifteen more. Each plaintiff alleged an intracranial meningioma caused by Depo-Provera or a generic version, with product liability and misrepresentation claims that largely matched.3
Both groups of plaintiffs who asked for centralization wanted the cases sent to California. Pfizer and its Pharmacia companies preferred the Southern District of New York. The panel chose the Northern District of Florida instead and assigned the docket to Judge M. Casey Rodgers in Pensacola, noting her experience with large product liability MDLs. It also kept Depo-SubQ Provera 104, the lower-dose shot given under the skin, inside the MDL for anyone who claims injury from it.3
The medical background, including the 2024 French study and the label change, is covered in the guide to Depo-Provera risks. This page follows the litigation from the transfer order to the settlement program.
From discovery to a global agreement
Judge Rodgers ran the case on a fast schedule. Every plaintiff had to upload initial documentary proof of using a named defendant’s product and initial proof of the meningioma, under Pretrial Orders 17 and 22, with BrownGreer PLC handling the data. Pfizer produced more than ten million pages of corporate records, plaintiffs’ leadership deposed five fact witnesses, and each side served general causation reports from five experts.1
Two threshold questions were briefed first: federal preemption and general causation, meaning whether the drug can cause meningioma at all. The first bellwether trial was set for December 7, 2026.1 On June 15, 2026, after the parties reported a global agreement, the court postponed its ruling on preemption and moved the hearing on the expert-evidence motions to July 27.4 The court’s July order records that the December trial was canceled and that the general causation hearing had been reset for September 18, 2026.2
The Master Settlement Agreement is a private, confidential contract. Case Management Order No. 12 says the parties signed it on July 21, 2026, while Case Management Order No. 14 describes an agreement dated July 22.2,1 Because MDL 3140 is not a class action, the court does not hold a fairness hearing on the terms, although Judge Rodgers wrote that the deal offers an excellent outcome to thousands of eligible litigants.2 Pfizer admits no fault or liability.1
Who is eligible for the Depo-Provera settlement
The eligibility rules are written into the Master Settlement Agreement and have not been made public. What the court has recorded is an estimate: the parties expected roughly 80 percent of all MDL plaintiffs to qualify. They also told the court that eligibility will not change with any later ruling on preemption or general causation.2 Those rulings would still matter for everyone outside the program.
The orders describe two groups that the agreement leaves out. Limitations Plaintiffs are ineligible because of the date they first sued. Latency Plaintiffs are ineligible because of the timing of the meningioma diagnosis compared with the last shot.1 The exact cutoffs sit in the confidential agreement.
The court’s orders deal with the federal MDL. When the settlement was announced, leadership counsel described it as covering a majority of claims in the MDL and in New York state court.2 As of July 27, 2026 the MDL held 6,289 cases. State courts held others: 129 cases in New York, 410 in Delaware, 118 in California, and 72 cases on behalf of 6,899 plaintiffs in Minnesota, with smaller groups elsewhere.2
The November 30, 2026 deadline
Case Management Order No. 14, entered August 10, 2026, records the court’s understanding that claimants must register for the settlement program by November 30, 2026. After that date the Settlement Administrator will identify to the court anyone found ineligible.1 As of November 2026 the court’s MDL page and its orders list show no later order that moves this date.5,6
A second deadline falls on the same day. To take part, a claimant has to have a complaint on file. Case Management Order No. 18, entered September 15, 2026, created a no-fee administrative docket for people who signed an engagement letter with a lawyer for a Depo-Provera claim on or before June 11, 2026, who are eligible, and who had not yet sued. Their lawyers must upload those complaints to BrownGreer through the Depo-Provera MDL Centrality portal on or before November 30, 2026.7
That docket exists only for settlement. If BrownGreer finds that a person filed there without meeting the criteria, the complaint moves to the active MDL docket, the standard filing fee becomes due within seven days, and an unpaid fee leads to dismissal. A transferred plaintiff becomes a Future Filed Plaintiff and is bound by every order on the active docket.7 At the July conference the parties projected that registration would close in November and that payments would begin to roll out by the first quarter of 2027.2
What a claimant must document
The settlement’s own claim forms are not public. The court’s orders show what the program checks. Every MDL plaintiff already had to produce initial proof of product use and of the meningioma diagnosis.1 BrownGreer, appointed Settlement Administrator on August 5, 2026, uses the information from claimants and their lawyers to decide eligibility, reviews all submissions and supporting records, and holds signed releases and stipulations of dismissal in trust. It also works with both sides on fraud protection, which includes rejecting fraudulent claims.8
Other appointments shape the paperwork. Matt Garretson of Garretson, LLC runs the Supplemental Compensation Fund, through which an eligible claimant may ask for additional compensation under criteria he develops.9 BrownGreer also serves as Lien Resolution Administrator, resolving liens for medical care against settlement awards, at the settling claimants’ expense.10
On October 29, 2026 the court approved the Depo-Provera Qualified Settlement Fund and a separate Common Benefit fund, with certified public accountant Randall L. Sansom as administrator. The fund will receive Pfizer’s payments, and its administrator reports to the court every quarter.11 No court order states the total amount.
Cases that do not join
Case Management Order No. 14 sets the rules for anyone who stays in court. It calls them Litigating Plaintiffs: eligible plaintiffs who do not take part, ineligible plaintiffs other than the Limitations and Latency groups, and people who file after August 10, 2026. All other proceedings are stayed while the program runs.1
The obligations are heavy. Within 60 days a Litigating Plaintiff must send preservation notices by certified mail to every doctor who treated her or prescribed the shot, and to employers and tax preparers if she claims lost wages. Within 90 days she must serve a Plaintiff Fact Sheet signed under penalty of perjury, a declaration of her first and last dates of use, full medical records on the diagnosis and treatment, and expert reports that tie her meningioma to the drug and rule out other causes. Template reports will be struck.1
Missing a deadline leads to a 30-day cure period, then a show cause order, then dismissal with prejudice. Plaintiffs who comply go to mediation before Magistrate Judge Hope T. Cannon for at least 90 days and must appear in person at a status conference in Pensacola, where an unexcused absence also means dismissal with prejudice. Only then does case-specific discovery open, for 180 days.1 New filers who say the meningioma came before March 27, 2024 must also certify within 30 days why the claim is not time-barred.1 For the Limitations and Latency groups, the court expects separate proceedings on those defenses.1
Plaintiff groups under Case Management Order No. 14
Swipe the table
| Group | Who belongs | What follows |
|---|---|---|
| Settling claimants | Eligible plaintiffs who register by November 30, 2026 | Review by BrownGreer; payments projected from early 2027 |
| Non-Settling Plaintiffs | Eligible plaintiffs with a pending case who do not take part | Preservation notices in 60 days, records and expert reports in 90 days, mediation, in-person conference |
| Ineligible Plaintiffs | Plaintiffs the administrator finds ineligible, other than the two groups below | The same obligations, counted from the date of the finding |
| Limitations Plaintiffs | Ineligible because of the date the lawsuit was filed | Separate proceedings on cross-cutting defenses |
| Latency Plaintiffs | Ineligible because of the gap between the last shot and the diagnosis | Separate proceedings on cross-cutting defenses |
| Future Filed Plaintiffs | Cases filed or transferred after August 10, 2026, outside the administrative docket | The same obligations, counted from filing; a limitations certification if the tumor predates March 27, 2024 |
Where to find official information
The court keeps a public page for MDL 3140 with the main orders and a list of orders by date. The next case management conference is set for December 18, 2026 at 9:00 a.m. Central time. The page notes that Pfizer maintains the drug is safe and effective, and it points to PACER for the full docket.5,6 The settlement orders are filed under master docket No. 3:25-md-3140.1
The court’s pages explain procedure, and the confidential agreement is not posted there. A claimant with a lawyer gets settlement information through that lawyer, who works with BrownGreer on MDL Centrality.7 Someone without a lawyer who believes she has a claim can ask a licensed attorney, or read the court’s orders on the MDL page, which also lists contacts for the court. More guides on contraception and women’s health are collected under Health.
Questions about the Depo-Provera settlement
What is the deadline for the Depo-Provera settlement?
Case Management Order No. 14 records November 30, 2026 as the deadline to register for the settlement program, and Case Management Order No. 18 sets the same date for lawyers to submit complaints on the no-fee administrative docket.1,7
How much is the Depo-Provera settlement worth?
The total has not been made public. The Master Settlement Agreement is confidential, and the court’s October 29, 2026 order setting up the settlement fund does not state an amount.2,11
When will Depo-Provera settlement payments be made?
At the July 2026 conference the parties projected that payments would begin to roll out by the first quarter of 2027. That is a projection, not a court deadline.2
What happens if a plaintiff does not join the settlement?
Her case continues under Case Management Order No. 14, with preservation notices, a sworn fact sheet, medical records and case-specific expert reports due on fixed deadlines, followed by mediation and an in-person conference. Missed deadlines can end in dismissal with prejudice.1
References
Sources 11
- ↩In re: Depo-Provera Products Liability Litigation, Case Management Order No. 14 (Case Management Order for Ongoing Litigation)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 738
- ↩In re: Depo-Provera Products Liability Litigation, Case Management Order No. 12U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 701
- ↩Transfer Order, In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability LitigationJudicial Panel on Multidistrict Litigation · MDL No. 3140
- ↩In re: Depo-Provera Products Liability Litigation, Pretrial Order No. 30A (Application of Rulings on Preemption and Rule 702 Motions to All Individual Actions)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 661
- ↩Depo-Provera Products Liability Litigation, MDL No. 3140U.S. District Court, N.D. Florida
- ↩MDL 3140 Orders by DateU.S. District Court, N.D. Florida
- ↩In re: Depo-Provera Products Liability Litigation, Case Management Order No. 18 (Establishment of Administrative Docket in Connection with Settlement)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 761
- ↩In re: Depo-Provera Products Liability Litigation, Case Management Order No. 13 (Appointment of Settlement Administrator)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 711
- ↩In re: Depo-Provera Products Liability Litigation, Case Management Order No. 15 (Appointment of Supplemental Compensation Fund Allocation Master)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 746
- ↩In re: Depo-Provera Products Liability Litigation, Case Management Order No. 17 (Appointment of Lien Resolution Administrator)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 748
- ↩In re: Depo-Provera Products Liability Litigation, Order (Establishment of the Qualified Settlement Fund and Common Benefit Fund)U.S. District Court, N.D. Florida · No. 3:25-md-3140, ECF No. 791